{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:26:25Z","timestamp":1786983985130,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.abd.2025.501132","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:19:49Z","timestamp":1750231189000},"page":"501132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of PASI90 response in patients with psoriasis treated with \u0131nterleukin \u0131nhibitors: observational cohort study"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5140-1926","authenticated-orcid":false,"given":"Burhan","family":"Engin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-5917","authenticated-orcid":false,"given":"Yusuf","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-4262","authenticated-orcid":false,"given":"Sera Nur","family":"Yucesoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-7638","authenticated-orcid":false,"given":"Tumay","family":"Ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501132_bib0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501132_bib0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/reum.2018.80718","article-title":"Psoriasis in special localizations","volume":"56","author":"Dopytalska","year":"2018","journal-title":"Reumatologia."},{"key":"10.1016\/j.abd.2025.501132_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.abd.2025.501132_bib0020","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2025.501132_bib0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","article-title":"The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients","volume":"28","author":"Abrouk","year":"2017","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2025.501132_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","article-title":"Treatment goals for psoriasis: should PASI 90 become the standard of care?","volume":"106","author":"Torres","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.abd.2025.501132_bib0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/jdv.14073","article-title":"Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial","volume":"31","author":"Lacour","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0045","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15285","article-title":"Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial","volume":"35","author":"Sigurgeirsson","year":"2022","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2025.501132_bib0050","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/jdv.16568","article-title":"A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)","volume":"34","author":"Seneschal","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0055","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2307\/2531021","article-title":"Sample-size formula for the proportional-hazards regression model","volume":"39","author":"Schoenfeld","year":"1983","journal-title":"Biometrics."},{"key":"10.1016\/j.abd.2025.501132_bib0060","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","article-title":"Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience","volume":"31","author":"Barker","year":"2020","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2025.501132_bib0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler","year":"1985","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0070","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1067\/mjd.2002.120470","article-title":"Psoriasis of early and late onset: a clinical and epidemiologic study from Spain","volume":"46","author":"Ferr\u00e1ndiz","year":"2002","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/09546634.2012.755258","article-title":"Current therapeutic approaches of psoriasis are affected by age at disease onset","volume":"25","author":"Di Lernia","year":"2014","journal-title":"J Dermatolog Treat."},{"key":"10.1016\/j.abd.2025.501132_bib0080","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40257-018-0388-z","article-title":"Effect of age of onset of psoriasis on clinical outcomes with systemic treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"19","author":"Singh","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0085","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/bjd.13865","article-title":"Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis","volume":"173","author":"Griffiths","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2340\/0001555577273276","article-title":"Evidence that HLA-Cw6 determines early onset of psoriasis, obtained using sequence-specific primers (PCR-SSP)","volume":"77","author":"Enerb\u00e4ck","year":"1997","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"10.1016\/j.abd.2025.501132_bib0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4103\/ijd.ijd_45_21","article-title":"Early-onset versus late-onset psoriasis: a comparative study of clinical variables, comorbidities, and association with HLA-CW6 in a tertiary care center","volume":"66","author":"Fatema","year":"2021","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.abd.2025.501132_bib0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/reum.2022.120752","article-title":"The role of HLA-Cw6 in psoriasis and psoriatic arthritis","volume":"60","author":"Owczarek","year":"2022","journal-title":"Reumatologia."},{"key":"10.1016\/j.abd.2025.501132_bib0105","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0110","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.283","article-title":"Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study","volume":"101","author":"Borroni","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0115","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s12325-022-02379-9","article-title":"Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting","volume":"40","author":"Lynde","year":"2023","journal-title":"Adv Ther."},{"key":"10.1016\/j.abd.2025.501132_bib0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1468-3083.2012.04496.x","article-title":"Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-na\u00efve vs. non-na\u00efve patients","volume":"27","author":"van L\u00fcmig","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0125","first-page":"1","article-title":"Validation and usability of modified palmoplantar psoriasis area and severity index in patients with palmoplantar psoriasis: a prospective longitudinal cohort study","author":"Nagendran","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"10.1016\/j.abd.2025.501132_bib0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.abd.2025.501132_bib0135","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 \u0131nhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0140","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ad.2018.03.016","article-title":"Selective Il-23 \u0131nhibitors: the new kids on the block in the treatment of psoriasis","volume":"109","author":"Torres","year":"2018","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.abd.2025.501132_bib0145","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.abd.2025.501132_bib0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0160","article-title":"Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: real-world practice","volume":"33","author":"Herrera-Acosta","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2025.501132_bib0165","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3700","article-title":"An analysis of patient-reported outcomes in IXORA-S: comparing \u0131xekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis","volume":"100","author":"Puig","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0170","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2012 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2025.501132_bib0175","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long\u2010term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate\u2010to\u2010severe psoriasis: results from the PHOENIX 2 study through 5-years of follow\u2010up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501132_bib0180","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1759720X17735756","article-title":"Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness","volume":"9","author":"Tsai","year":"2017","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"10.1016\/j.abd.2025.501132_bib0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0200","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501132_bib0205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12962-023-00504-1","article-title":"Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi Arabia","volume":"21","author":"AlRuthia","year":"2023","journal-title":"Cost Eff Resour Alloc."},{"key":"10.1016\/j.abd.2025.501132_bib0210","doi-asserted-by":"crossref","first-page":"953","DOI":"10.5114\/ada.2022.120886","article-title":"Efficacy of guselkumab compared with adalimumab for psoriasis: a meta-analysis of randomized controlled studies","volume":"39","author":"Fu","year":"2022","journal-title":"Postepy Dermatol Alergol."},{"key":"10.1016\/j.abd.2025.501132_bib0215","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501132_bib0220","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2025.501132_bib0225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0230","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res."},{"key":"10.1016\/j.abd.2025.501132_bib0235","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0240","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s13555-021-00679-6","article-title":"Efficacy of Risankizumab versus Secukinumab in patients with moderate-to-severe Psoriasis: subgroup analysis from the IMMerge study","volume":"12","author":"Crowley","year":"2022","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2025.501132_bib0245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501132_bib0250","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501132_bib0255","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2025.501132_bib0260","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.206","article-title":"Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity \u0131ndex scores in a prospective multicentre cohort","volume":"102","author":"Van Muijen","year":"2022","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0265","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/jdv.18376","article-title":"Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)","volume":"36","author":"Pinter","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501132_bib0270","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501132_bib0275","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/1346-8138.15004","article-title":"Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: subgroup analysis from the CLEAR study","volume":"46","author":"Lee","year":"2019","journal-title":"J Dermatol."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:21:16Z","timestamp":1753888876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0365059625000741"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501132","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of PASI90 response in patients with psoriasis treated with \u0131nterleukin \u0131nhibitors: observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501132"}}